Genetic insights into the age-specific biological mechanisms governing human ovarian ageing

Sven E. Ojavee^{1,2,*}, Liza Darrous^{1,2,3}, Marion Patxot^{1,2}, Kristi Läll⁴, Krista Fischer^{4,5}, Reedik Mägi⁴, Zoltan Kutalik^{1,2,3,†}, Matthew R. Robinson^{6,*,†}

Department of Computational Biology, University of Lausanne, Lausanne, Switzerland.
 ² Swiss Institute of Bioinformatics, Lausanne, Switzerland

³ University Center for Primary Care and Public Health, Lausanne, Switzerland

⁴ Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia

 $^{\mathbf{5}}$ Institute of Mathematics and Statistics, University of Tartu, Tartu, Estonia

⁶ Institute of Science and Technology Austria, Klosterneuburg, Austria.

*corresponding author: matthew.robinson@ist.ac.at † indicates joint supervision

Abstract

There is currently little evidence that the genetic basis of human phenotype varies significantly across the lifespan. However, time-to-event phenotypes are understudied and can be thought of as reflecting an underlying hazard, which is unlikely to be constant through life when values take a broad range. Here, we find that 74% of 245 genome-wide significant genetic associations with age at natural menopause (ANM) in the UK Biobank show a form of age-specific effect. Nineteen of these replicated discoveries are identified only by our modelling framework, which determines the time-dependency of DNA variant-age-at-onset associations, without a significant multiple-testing burden. Across the range of early to late menopause, we find evidence for significantly different underlying biological pathways, changes in the sign of genetic correlations of ANM to health indicators and outcomes, and differences in inferred causal relationships. We find that DNA damage response processes only act to shape ovarian reserve and depletion for women of early ANM. Genetically mediated delays in ANM were associated with increased relative risk of breast cancer and leiomyoma at all ages, and with high cholesterol and heart failure for late-ANM women. These findings suggest that a better understanding of the age-dependency of genetic risk factor relationships among health indicators and outcomes is achievable through appropriate statistical modelling of large-scale biobank data.

Introduction

Age-at-onset and time-to-event observations are among the most important traits of interest in cohort studies of age-related diseases, as they are critical to gaining insight into the genetics of disease development and progression [1,2]. The underlying aetiology of age-related outcomes likely reflects a variety of biological processes that are triggered at different stages of life, long before the onset of observable symptoms. As a result, the underlying genetic propensity for outcomes may vary with age, and depend upon different sets of genetic risk factors at different time points, reflecting the 7

1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

range of underlying molecular mechanisms that shape the onset distribution. Therefore, identifying ⁸ the genetic variants associated with onset at different stages of life will improve our understanding ⁹ of disease progression. ¹⁰

Here, we seek to test the hypothesis that genetic propensity for age-at-onset is age-specific, by 11 focusing on the most commonly experienced timing-related phenotype in the human population, 12 age at natural menopause (ANM). Menopause is the permanent cessation of the menstrual cycle in 13 women following the loss of ovarian function and occurs at an average age of 51 years, with 4% of 14 the female population experiencing early menopause prior to age 45. Current evidence suggests that 15 early menopause is associated with a risk for cardiovascular disease [3] and osteoporosis [4], and late 16 menopause is associated with a risk for breast cancer [5]. Recent genomic studies, find $\sim 50\%$ of 17 menopausal timing variation is attributable to genetic markers [6] that are linked to regulation of 18 DNA repair and immune function [7–9]. However, previous analyses make strong assumptions that 19 genetic effects are constant throughout life (Figure 1a). By modelling the quantitative genetic basis 20 of ANM in a way that enables detection of the age at which genetic risk factors have the greatest 21 influence, we report evidence for widespread age-specific genetic effects underlying population-level 22 variation in ovarian ageing in both the UK and Estonian Biobank data. 23

Results

Modelling effect size change reveals novel loci

Summary of the methods

In the Methods, we present a marginal Cox Age-specific Mixed Proportional hazards model (CAMP) with a novel significance testing framework. CAMP determines the time-dependency of markerage-at-onset associations, without a significant multiple-testing burden. Our two-step approach is a form of parametric Weibull survival analysis, followed by an age-specific Cox proportional hazards model for single marker association testing that can capture the change in genetic hazard for age-at-onset while controlling for the off-locus genetic effects in a mixed-model approximating fashion. Linear-mixed model association testing is widely applied in the genomics field, but here it is explicitly tailored for age-at-onset outcomes with right censoring. In this two-step approach, we first use a BayesW prior [1] to estimate the genetic effects for age-at-onset jointly. That creates the leave-one-chromosome-out genetic predictors that are then used in the age-specific Cox proportional hazards model of the second step. Hence, the final model shape for individual i, chromosome k and SNP j is

$$\lambda_i(t) = \lambda_0(t) \exp\left(\mathbf{x}_{ij}\boldsymbol{\beta}_j(t) + \mathbf{g}_i^k \boldsymbol{\xi}_j + \mathbf{z}_i \boldsymbol{\delta}_j\right),\,$$

where $\lambda_0(t)$ is the baseline hazard, \mathbf{x}_{ij} is the standardised genotype for the *j*th marker, \mathbf{g}_i^k is the 27 BayesW genetic predictor for individual *i* from all chromosomes other than *k*, $\boldsymbol{\xi}_j$ is its corresponding 28 effect when estimating marker *j*, \mathbf{z}_i is the summarised covariate value and $\boldsymbol{\delta}_j$ is its corresponding 29 effect when estimating marker *j*. $\boldsymbol{\beta}_j(t) = \boldsymbol{\beta}_j^0 + \boldsymbol{\beta}_j^1(t-t_0)$ is the effect size change function for SNP 30 *j* which we assume is a linear function ($\boldsymbol{\beta}_j^0$ is the intercept, $\boldsymbol{\beta}_j^1$ is the slope, t_0 is an offset specifying 31 the intercept interpretation, see Methods). We then test for age-at-onset associations for every SNP 32 given our theoretically supported significance testing procedure (see Methods). 33

24

25

Discovery of novel loci

We apply our CAMP model to 173,424 unrelated observations of self-reported ANM in the UK 35 Biobank data (125,697 reported events and 47,727 right-censored observations; 8,747,951 SNPs), 36 and 70,082 observations in the Estonian Biobank (22,740 reported events and 47,342 censored 37 observations, Figure S1). We find 312 ANM associations in the UK Biobank, of which 226 replicate 38 previous studies [7–9], and 19 are novel and replicate for the first time within the Estonian Biobank 39 (Table 1, Figure 1b, see Figure S2). In addition, we find 67 associations that have not previously 40 been reported, but they did not replicate in the Estonian Biobank. Nevertheless, 46 out of 67 41 previously unreported associations show consistency with signs in the discovery and replication 42 data sets (Fisher's exact test, p = 0.007), suggesting that a larger replication data set could lead 43 to further replications. In conclusion, the CAMP approach yields a power increase: 8% of the 44 replicated marker associations are previously unreported, an increase consistent with the increased 45 power of our approach. 46

Proportion of age-specific effects

47

34

For quantifying the existence of age-specific effects, we first test the null hypothesis of whether the slope term β_j^1 is different from 0, with a rejection of the null implying the existence of a time-varying genetic effect. Of the 245 UK Biobank associations, we find that 72% (176) show at least nominally significant (p < 0.05) age-specific effects within UK women (Figure 2c). Applying a more stringent




Figure 1. Statistical model description and novel discoveries. (a) The CAMP model enables a more flexible and accurate description of the SNP effect size by introducing a slope term. The linear change model enables three example questions to be addressed: i) what is the interval at which there is a significant effect on the trait? ii) at which age is there strongest evidence for an effect? iii) is the slope (β_1) significantly different from zero? Even though a more complex model can result in generally wider confidence intervals, it can still result in a more accurate representation of the effect size, often accompanied by higher statistical power. By estimating the effect size change it is also possible to accurately determine trends, which constant effect assumptions cannot capture. (b) 19 novel discoveries for age-at-menopause from the CAMP model across the UK and Estonian Biobank data, the coral line indicates the genome-wide significance level of $5 \cdot 10^{-8}$.

criterion, 37 of these 176 associations, 15% of all associations, have a slope with a genome-wide 52 significant p-value. In total, we find 63 regions that exhibit a genome-wide significant slope term 53 in the UK Biobank (Tables 2, S1), and we replicate the age-specific effects for 20 regions in the 54 Estonian Biobank (Table 2) yielding a replication rate of 32% (Figure 2c). These 20 variants 55 have stronger effect sizes earlier in life that mostly decay toward zero after age 50 (Figure S5), 56 making them early-ANM specific. Although 139 variants do not pass the threshold for genome-wide 57 significance, they still indicate that for many regions previously identified as menopause-associated, 58 the assumption of constant effect size (assumption of proportional hazards at the SNP) is generally 59 invalid. Indeed, the 43 UK Biobank discovered variants with significant slope terms that did not 60 replicate in the Estonian Biobank had effect size directions that were broadly concordant across 61 studies (Fisher's exact test p = 0.051, Table S1). 62

Second, as the model is age-specific, we test for significance at time points where the evidence is 63 the highest within the intervals 41 to 55 (see Methods). For significant SNPs detected in the UK 64 Biobank, the age distribution of maximum association evidence is concentrated between the ages 65 of 43 and 51 (Figure S3). That is different compared to the maximum association evidence age 66 distribution for all SNPs, which has thicker tails with nearly four times higher standard deviation 67 even if the distributions have similar centres (median age of 51 and 49 for all SNPs and significant 68 SNPs, respectively) (Figure S3). We observe that the number of regions affecting ANM changes 69 considerably with the peak number of ANM-affecting regions observed at age 49 (Figure 2a). 70 Moreover, we find that the period during which a particular region can significantly impact ANM 71

						Maximum	Age-at		Effect	Yearly
SNP	Chr	Position	Eff/Oth	MAF	Nearest gene	effect	maximum	p-value	at 49	effect change
rs16852403	1	178,039,226	C/T	0.200	RASAL2-AS1*	0.026	45.0	5.70×10^{-9}	0.014	-0.0032
rs60897342	1	235,512,110	T/C	0.475	GGPS1*	-0.018	49.6	4.32×10^{-10}	-0.018	0.0008
rs77629370	2	27,251,504	T/C	0.062	MAPRE3*	0.023	48.7	3.52×10^{-14}	0.022	-0.0017
rs6544660	2	$43,\!688,\!496$	C/T	0.451	THADA	-0.021	48.8	7.22×10^{-12}	-0.020	0.0016
rs16839858	2	204,366,776	A/G	0.166	RAPH1	-0.017	51.0	1.30×10^{-9}	-0.016	-0.0005
rs6443930	3	183,754,294	C/G	0.439	HTR3D	0.022	50.1	2.15×10^{-14}	0.022	-0.0004
rs816734	5	$154,\!272,\!947$	T/C	0.350	GEMIN5	0.021	47.9	1.26×10^{-10}	0.019	-0.0022
rs142490551	5	176, 369, 037	C/G	0.019	UIMC1	0.021	49.9	3.31×10^{-14}	0.021	-0.0003
rs191306205	6	31,739,684	T/C	0.025	VWA7	0.020	48.5	1.36×10^{-11}	0.020	-0.0016
rs60375899	7	860,846	A/G	0.130	SUN1	0.020	49.5	3.93×10^{-12}	0.020	-0.0009
rs2905065	9	136,958,528	C/T	0.326	RP11-349K21.1*	0.027	48.0	1.65×10^{-16}	0.024	-0.0026
rs7946546	11	63, 595, 648	G/A	0.473	C11orf84*	0.018	51.8	3.32×10^{-9}	0.014	0.0012
rs17180987	12	66,844,882	A/G	0.018	GRIP1	-0.021	47.8	3.60×10^{-9}	-0.018	0.0024
rs1285841	14	91,881,387	T/C	0.443	CCDC88C	-0.022	47.4	3.36×10^{-10}	-0.018	0.0024
rs143569302	15	41,258,121	T/C	0.040	CHAC1*	0.021	49.4	1.37×10^{-13}	0.022	-0.0009
rs11638671	15	63,795,628	C/T	0.344	USP3*	-0.031	45.0	2.10×10^{-11}	-0.015	0.0039
rs11647700	16	12,108,743	T/C	0.073	SNX29	0.020	50.3	9.58×10^{-13}	0.020	0.0000
rs9807043	17	48,875,077	T/C	0.158	RP11-294J22.5*	0.017	49.5	1.65×10^{-9}	0.018	-0.0008
rs118159243	17	62, 633, 136	C/G	0.017	SMURF2	0.020	47.7	6.99×10^{-10}	0.017	-0.0019

Table 1. Previously undiscovered regions affecting age-at-menopause. For 8.7M SNPs, we determined the age at which there is the strongest evidence for an effect within the CAMP model. Then given the age identified for each SNP, we tested for significance at this age using the CAMP model results, and we obtained effect size and standard error estimates. The results were then LD clumped such that the index SNPs would have a p-value below $5 \cdot 10^{-8}$ and SNPs could be added to a clump if they were 1Mb from the index SNP, they were correlated with $r^2 > 0.05$ and they were nominally significant (p < 0.05). We then used the COJO method from the GCTA software (see Methods) to find clumps with independent signals by conducting a stepwise selection of index SNPs in a 1Mb window and we considered SNPs independent if they had a p-value below $5 \cdot 10^{-8}$ in the joint model. To determine novely, we then removed all the markers that had a correlation of $r^2 > 0.1$ with a marker that had been previously found associated with age-at-menopause using the GWAS Catalog and LDtrait tool with the British in England and Scotland population. For the remaining SNPs, we conducted an additional literature review using the Phenoscanner database (see Methods) to find any previous associations with variants of interest or variants in LD. The remaining candidates for novel associations were then tested in the Estonian Biobank. Replication was defined as a p-value lower than 0.05 and the direction of the effect size same in both the original analysis and the replication analysis. The effect size estimates are reported on the log hazard scale. The column named, nearest gene, is mapped from the SNP using ANNOVAR software.






Figure 2. Age distribution of significant effects and effect size change. (a) We evaluated the significance of every SNP at each age on a grid from 41 to 55 and counted the number of significant hits replicated in the Estonian Biobank. The significant focal hits were mapped to consecutive ages, summarising the count since when the effects were significant; (b) Effect sizes (log HR) for 245 significant effects, the majority of variants have a larger absolute effect size at age 41 than at age 55, only nine variants have an increasing effect size. We observe that the model manages to capture the effect size change for many variants; (c) Classification of the menopause-associated variants by age-specific evidence by testing whether the slope parameter is equal to zero. Variants with weak evidence have a p-value lower than p < 0.05, moderate evidence requires $p < 5 \cdot 10^{-8}$, and strong evidence requires the slope to be significant also in the replication data set.

varies considerably with only half of the significant associations at age 47 also significant at age 41. 72 In general, we observe that effects tend to become insignificant with increasing age, with the drop in 73 significance occurring at age 53, so that by age 55 only 8 loci have a genome-wide significant effect 74 on age-at-menopause (Figure 2a). A similar result can be seen if we observe the distribution of ages 75 when the evidence for the menopause effect is the strongest (Figure S3), as very few significant 76 SNPs achieve the strongest association after age 51. 77

In contrast to most associations discovered at age 49, the general trend across 245 significant 78 SNPs is that the effect size estimates shrink towards zero (Figure 2b). That might imply that the 79 increase in the number of discoveries in the period 41 to 49 is instead due to the reduction in the 80 standard error, and with a higher sample size, it could be possible to detect more associations 81 already at earlier ages. Interestingly, only nine of the significant SNPs have a larger absolute effect 82 size at age 55 than at 41. That is in line with many previous results reporting a reduction in relative 83 genetic risks with the increase in age [10, 11]. Finally, we observe that there exists a stark difference 84 between the effect size profiles of significant and insignificant effects (Figure S4) with a much 85 narrower effect size distribution for the non-significant SNPs. Meanwhile, menopause-associated 86 variants stand out as their effect size can change greatly across the period of interest. 87

Our analysis differs in one other key way from previous ANM genetic association studies. Here, 88 we do not censor women who were placed on hormone replacement therapy (HRT). In survival 89

models, declaring HRT individuals as censored makes the modelling assumption that age-at-HRT 90 start and ANM are independent. They are clearly not as for women on HRT, there is a correlation 91 between the age of HRT and ANM of 0.58 within the UK Biobank. For women who were placed on 92 HRT prior to the recorded date of ANM, this correlation is stronger at 0.69. A Cox Proportional 93 Hazards model for ANM including a categorical covariate of whether a woman was given HRT prior 94 to menopause (1 if on HRT prior to menopause, 0 otherwise), shows that censoring for HRT prior 95 to ANM, would significantly censor for earlier menopause (HR = 0.95, $p = 6.08 \cdot 10^{-15}$). Thus, 96 censoring for HRT is not the optimal modelling choice and additionally, it results in the loss of 97 34,031 observations, reducing power. Nevertheless, we conduct a sensitivity analysis of our estimated 98 effect sizes with and without adding HRT as a time-varying covariate to the CAMP model, at the 99 312 top loci identified within our study (Figure S6). We find very strong concordance of effect 100 sizes across loci (Figure S6), highlighting that in practice these different modelling choices have no 101 detectable impact on the leading SNP association findings. 102

Properties of novel and age-specific genetic associations

We conduct a number of follow-up analyses to support our age-specific association results. First, we 104 test for significant enrichment of the summary statistics generated by our approach for each age 105 group. For all categories showing significant enrichment after Bonferroni multiple testing correction, 106 we find that their significance does not hold across all age groups (Figure 3 and Table S3 to Table 107 S10).

Effect sizes for ANM between the ages of 41 to 49 were enriched in genes differentially expressed 109

					Nearest	Yearly		Strongest
SNP	Chr	Position	Eff/Oth	MAF	gene	effect change	Slope p-value	evidence p-value
rs6684319	1	39,334,988	A/G	0.310	MYCBP	0.0061	1.12×10^{-19}	9.63×10^{-57}
rs185012833	2	62,779,457	C/A	0.003	PSAT1P2*	-0.0033	6.03×10^{-9}	1.81×10^{-6}
rs6760293	2	171, 816, 531	A/T	0.373	GORASP2	-0.0040	1.36×10^{-9}	7.33×10^{-34}
rs12503643	4	185,746,088	T/G	0.399	ACSL1	0.0049	3.05×10^{-13}	4.28×10^{-61}
rs274722	5	6,718,668	T/C	0.406	PAPD7	-0.0040	1.06×10^{-9}	3.64×10^{-25}
rs58400555	5	176,454,081	T/A	0.484	ZNF346	0.0039	5.34×10^{-9}	3.21×10^{-179}
rs2077491	6	31,606,376	C/T	0.473	BAG6*	0.0053	1.67×10^{-15}	1.06×10^{-60}
rs728900	10	131,590,300	A/T	0.420	RP11-109A6.3*	-0.0050	5.79×10^{-14}	4.19×10^{-28}
rs75770066	12	66,704,225	G/A	0.033	HELB	0.0049	6.62×10^{-12}	1.58×10^{-212}
rs11638671	15	63,795,628	C/T	0.344	USP3*	0.0039	3.62×10^{-9}	1.09×10^{-10}
rs33650	16	11,978,769	C/T	0.385	GSPT1	0.0042	3.28×10^{-10}	6.75×10^{-65}
rs1433753	16	34,879,951	T/C	0.441	RP11-14K3.1*	-0.0048	4.21×10^{-13}	2.26×10^{-23}
rs8071278	17	41,193,910	T/A	0.335	BRCA1*	0.0048	5.01×10^{-13}	4.70×10^{-50}
rs1991401	17	62,502,435	G/A	0.310	DDX5	-0.0048	2.51×10^{-13}	2.96×10^{-36}
rs16960290	19	55,799,918	T/C	0.433	BRSK1	0.0079	2.80×10^{-32}	1.11×10^{-86}
rs117146677	19	55,833,868	A/G	0.009	TMEM150B	-0.0053	1.50×10^{-18}	1.61×10^{-43}
rs299163	19	56,321,414	C/A	0.066	NLRP11	0.0042	4.26×10^{-10}	8.36×10^{-17}
rs8124538	20	61,300,863	A/G	0.212	SLCO4A1	-0.0039	1.65×10^{-9}	3.63×10^{-54}
rs6631137	х	30,665,762	C/T	0.316	GK*	-0.0064	1.60×10^{-22}	5.43×10^{-43}
rs67596711	х	152,638,744	G/T	0.499	ZNF275*	0.0055	1.28×10^{-16}	3.82×10^{-26}

Table 2. Regions with a genome-wide significant age-specific effect on age-at-natural menopause replicated in the Estonian Biobank. For each SNP, we tested the significance of the slope parameter using the CAMP model. The results were then LD clumped such that the index SNPs would have a p-value below $5 \cdot 10^{-8}$ and SNPs could be added to a clump if they were 1Mb from the index SNP, they were correlated with $r^2 > 0.05$ and they were nominally significant (p < 0.05). We then used the COJO method from the GCTA software (see Methods) to find clumps with independent signals by conducting a stepwise selection of index SNPs in a 1Mb window and we considered SNPs independent if they had a p-value below $5 \cdot 10^{-8}$ in the joint model. The candidates for significant slope were then replicated in the Estonian Biobank. Replication was defined as a p-value lower than 0.05 and the direction of the effect size same in both the original analysis and the replication analysis. The effect size estimates are reported on the log hazard scale. The column named, nearest gene, is mapped from the SNP using ANNOVAR software, a * in that column denotes intergenic regions; chromosome X nearest gene was determined by using the UCSC Genome Browser. The column named, strongest evidence p-value, indicates the p-value at the age when there is the strongest evidence for an effect.

108




Figure 3. Age-specific enrichment of genetic associations across multiple genomics resources. We evaluated the significance of every SNP at each age on a grid from 41 to 55 and from the resulting summary statistics we tested for enrichment across multiple genomics resources. Circle circumference gives the $-\log_{10}$ p-value and the colour gives the enrichment z-score calculated from the Downstreamer software. GTEx tissue-specific expression and GO terms are given on the y-axis for annotations with genome-wide significance after multiple testing correction at one or more age groups. Full results are given in Table S3 to Table S10.

in the uterus, thyroid, prostate, ovary, fallopian tubes, and cervix within the GTEx consortium data ¹¹⁰ (Figure 3). Additionally, we find enrichment between the ages of 41 and 49 for KEGG pathway ¹¹¹ NOTCH signalling associated with cell proliferation and death, the GO terms for an intrinsic ¹¹² pathway for apoptosis, and BH3-only proteins (Figure 3). In contrast, associations with variation ¹¹³ in ANM for individuals older than 51 were all enriched for genes with differential expression in ¹¹⁴ several brain regions within the GTEx data, with no evidence for enrichment in reproductive tissues ¹¹⁵ (Figure 3). These results suggest that genetic effects may differ across the age range. ¹¹⁶

Our next follow-up analysis used LD Score regression, where we find that genetic correlations ¹¹⁷ across ages are significantly less than 1 (Figure 4a). Genetic correlations of ANM and other ¹¹⁸ phenotypes were also largely age-dependent (Figure 4b). Note here that effect size estimates for ¹¹⁹ ANM are calculated on the menopause hazard scale and thus a positive correlation estimated by LD ¹²⁰ Score regression would refer to a high hazard of ANM (earlier ANM) corresponding to high trait ¹²¹ values, in other words, the observed value of ANM and the trait are in fact negatively correlated. ¹²² Thus, to ease interpretation we flip the sign of the estimated correlation to display the genetic ¹²³






Figure 4. Age-specific genetic correlations and causality of ANM and health-related outcomes. We evaluated the significance of every SNP at each age on a grid from 41 to 55 and from the resulting summary statistics we tested for genetic correlations among (a) age groups and (b) among observed ANM values at the age groups and 100 other health-related indicators and outcomes, using LD Score regression. In (b), we present correlations for outcomes with evidence of a significant non-zero genetic correlation at one age group or more. In (c), we present results from inverse-weighted Mendelian Randomization that estimates the potential causal relationship between ANM and outcomes where a significant genetic correlation was found in (b) across ages. Black boxes depict ages for which significant causal estimates were found. Full results from a range of Mendelian Randomisation models are given in Table S11.

correlation of the observed values of ANM and each trait.

124

Between 41 and 49 years, we find a significant positive genetic correlation of observed ANM 125 values with age at last birth and age at first birth (Figure 4b), implying a genetic relationship 126 between later reproduction and later ANM, for women whose ANM is earlier than average. 127

Of significant note, genetic propensity for breast cancer was significantly associated with a later 128 ANM (Figure 4b), before age 51. This supports previous evidence, where genetically mediated 129 delays in ANM were found to increase the relative risks of several hormone-sensitive cancers [8]. 130 Additionally, evidence linking exposure to high levels of estrogen hormones to an increased risk of 131 breast cancer is supported by a significant positive genetic correlation of ANM and oestradiol levels 132 for women of early menopause, implying a genetic propensity for high estrogen levels associated with 133 a genetic propensity for a later ANM (Figure 4b). Furthermore, we find that a high genetic risk for 134

leiomyoma is consistently associated with later ANM (Figure 4b). Together, with our enrichment results presented above (Figure 3) showing early ANM genetic associations are enriched for genes differentially expressed female reproductive organ, oocytes, and DNA damage repair mechanisms, our findings suggest that at the genetic level, breast cancer risk, hormone levels and ANM are intrinsically linked prior to age 50.

We also find significant genetic correlations implying that genetically mediated later ANM is ¹⁴⁰ correlated with a lower genetic predisposition to hypothyroidism, stroke, major depression, blood ¹⁴¹ albumin levels, and obesity prior to age 51 (Figure 3). For women at later ages, we find positive ¹⁴² genetic correlations of ANM with cholesterol, LDL, obesity, and heart failure, implying that later ¹⁴³ ANM is correlated with an increased genetic predisposition for these metabolic-associated health ¹⁴⁴ measures (Figure 3). ¹⁴⁵

We find a significant positive genetic correlation of ANM values with both educational attainment ¹⁴⁶ and fluid intelligence between 41 and 49 years (Figure 4b), implying a genetic relationship between ¹⁴⁷ later reproduction, higher education and later ANM, for women before the age of 50. Interestingly, ¹⁴⁸ these genetic correlations also significantly change in the sign for women whose ANM occurred after ¹⁴⁹ age 53, with a significant negative genetic correlation of ANM with educational attainment and ¹⁵⁰ fluid intelligence (Figure 4b), implying delayed reproduction and high educational attainment are ¹⁵¹ associated with reproductive senescence post-age 50. ¹⁵²

In a further follow-up analysis, we used Mendelian Randomisation (MR), which utilizes the 153 randomized inheritance of genetic variations in the population to estimate the potential causal 154 effect a modifiable risk factor or exposure has on a health-related outcome of interest. We used 155 menopause at different ages as an exposure in five different MR methods (Weighted median, Inverse 156 variance weighted, Simple mode, Weighted mode, and MR-Egger, see Table S11) found in the 157 'TwoSampleMR' R package. Note here again that effect size estimates for ANM are calculated 158 on the menopause hazard scale and thus to ease interpretation, we flip the sign of the estimated 159 potential causal effect to give values on the observed ANM scale. When repeating the analysis for 160 each varying age of our exposure, we find changes in the magnitude of the potential causal effect 161 with age for educational attainment, leiomyoma, oestradiol, and neutrophil count (Figure 4c). 162

Finally, we highlight notable examples of the novel replicated associations with significant slope 163 terms, such as chr11:63,595,648 which is downstream of the SPINDOC gene, where menopause 164 genetic risk increases with age, with the highest effect size at later age groups. Also, chr15:63,795,628 165 which is upstream of the USP3 gene where the menopause association disappears with increasing 166 age. Both of these associations were previously suggestively associated with age-at-menopause, but 167 passed the significance threshold in the UK Biobank and replicate in the Estonian Biobank using 168 our proposed model. 169

Discussion

170

Taken together, we find that the majority of ANM genetic associations display some form of agespecificity in their effects. In turn, that translates into the associations being differentially enriched in different biological pathways across ages, which then leads to different genetic associations of ANM and other health indicators and outcomes depending upon the timing of ANM, with different 172

175

potential statistical causal relationships.

We find evidence that prolonged and delayed reproduction are genetically associated with 176 reproductive senescence post-age 50 as the genetic correlations significantly change in the sign for 177 women whose ANM occurred after age 53, with a significant negative genetic correlation of ANM 178 with age at last birth and age at first birth (Figure 4b). Similarly, we find genetic correlations 179 between ANM and educational attainment or fluid intelligence significantly turn negative for women 180 whose ANM occurred after age 53. The latter patterns of changing genetic correlation may simply 181 reflect reproductive choices of the timing and number of children made in the human population 182 that are associated with levels of educational attainment. 183

Complementing the results from genetic correlations, our enrichment analysis results (Figure 184 3) show early ANM genetic associations being enriched for genes differentially expressed in female 185 reproductive organs, oocvtes, and DNA damage repair mechanisms. Hence, our findings suggest 186 that at the genetic level, breast cancer risk, hormone levels and ANM are intrinsically linked prior 187 to age 50. The patterns observed in the MR analyses largely reflect those of the genetic correlations 188 described above, but here we find little evidence for a causal relationship between ANM and breast 189 cancer, nor heart failure, age at first or last birth, or hypothyroidism (Figure 4c). That implies that 190 genetic correlation estimates likely reflect reverse causation or the presence of heritable confounders 191 of the trait pairs. 192

Our enrichment analysis findings support a link between DNA damage repair genes and repair and 193 surveillance for the development of oocvtes for early-ANM women. The size of the initial oocvte pool 194 at birth, along with the rate of atresia, influences the age at which the oocyte pool is depleted. The 195 meiosis that occurs in oocytes necessitates programmed double-stranded breaks (DSBs) that must be 196 repaired through the homologous recombination pathway, with oocytes that do not properly repair 197 DSBs after this first phase of meiosis undergoing apoptosis. Here, early-ANM-associated common 198 variants are enriched at loci harbouring genes involved in the DNA repair, and replication checkpoint 199 processes, such as RNA polymerase II, histone methyltransferase complex and histone acetvlation 200 (Figure 3). One-carbon metabolism has the ability to regulate the estrus cycle and modulate the 201 initiation of reproductive senescence through the loss of methyl-donor production needed to properly 202 maintain the epigenome. Our results support the existence of this mechanism as early-menopause 203 associations are enriched in pathways associated with the hypothalamic-pituitary-gonadal (HPG) 204 axis and with methylation in the nucleosome, with later-menopausal genetic associations showing 205 no evidence of enrichment in these pathways (Figure 3). In humans, it has been suggested that 206 postmenopausal women exhibit accelerated ageing compared with premenopausal women of the 207 same biological age [12]. However, the cause-effect relationship between epigenetic changes and 208 reproductive senescence remains unclear and our results imply early-ANM women may have a 209 methylation pattern associated with one-carbon metabolism that differs from the general population. 210 Generally, our follow-up analyses support previous studies [9, 13], but we demonstrate that almost 211 all underlying pathways associated with variation in ANM act in an age-specific manner. 212

There are several important caveats to our study. Firstly, we have assumed that the effect 213 size can only change linearly with age, whereas in reality, they could consist of more complicated 214 patterns that could be captured with piece-wise exponential models. However, introducing many 215 more parameters on a genome-wide scale would lead to a high multiple-testing burden, potentially 216

hampering the capability to detect the actual signal. Furthermore, especially for traits with a 217 moderate range of values (90% of the observed ANM happen between ages 45 to 55, Figure S1), 218 introducing many parameters could lead to overfitting. Therefore, we find that, especially in the 219 context of traits such as age-at-menopause, assuming a linear effect change is a suitable compromise 220 between the added value of learning new information about effect change and limiting the model 221 complexity without damaging the statistical power. Nevertheless, the analyses presented here 222 represent a first step, and we encourage specifying different functional forms for the effect size, 223 preferably for traits with a broader range of values or a reasonable prior guess. 224

Second, the current implementation of the model is not computationally efficient and to handle the computational burden we have utilised the computational resources of two universities to produce these results. Our objective was simply to simply highlight the existence of changing genetic relationships between phenotypes and health outcomes across the lifespan. Although it is possible to make marginal analyses embarrassingly parallel, it is inherently time-consuming to fit an age-specific Cox proportional hazards model. Scaling the inference requires new research into novel algorithms for computationally heavy high-dimensional statistical problems of this kind.

Finally, our study focused only on European ancestry individuals in the UK and Estonian ²³² Biobanks, and future analyses must take into account populations with more diverse ancestries to ²³³ get a fuller picture of the genetic architecture of age-at-menopause across the globe. This requires ²³⁴ research into statistical models that are capable of learning both shared and unique age-dependent ²³⁵ effect sizes across populations and it requires large-scale data to be collected from worldwide ²³⁶ populations. ²³⁷

In summary, we propose a novel analysis approach for GWAS of age-at-onset phenotypes, using 238 a two-stage MLMA model, where marker effect sizes are estimated using an age-specific Cox 239 proportional hazards model. Our approach provides a better understanding of the genetic basis of 240 age-at-menopause and applies to any form of time-to-event phenotype. 241

Methods

242

243

Marginal Age-specific Mixed Cox Proportional hazards model

Following the success of many GWASs, more attention has been attributed to better characterising the SNP effect behaviour under different environmental conditions, leading to genotype-covariate analyses [14]. For a continuous trait, one of the simplest ways to model this type of interaction would be to include a linear interaction term. For example, to estimate the impact of age on SNP effects, we could write the model as: 248

$$y_i = \mu + x_{ij}\beta_j^0 + x_{ij}(t_i - t_0)\beta_j^1 + \varepsilon_i, \qquad (1)$$

where (for individual *i* and SNP *j*) y_i is a continuous trait, μ is the intercept, x_{ij} is the SNP value, ²⁴⁹ β_j^0 is the SNP effect at time t_0 , t_i is the age when y_{ij} is measured, β_j^1 is the linear effect of age and ²⁵⁰ ε_i is the residual variance. However, for age-at-onset phenotypes, the model as specified in Equation ²⁵¹ 1 would not be identifiable since $y_i = t_i$. Previous studies have proposed to analyse age-specific ²⁵² effects by splitting time scales into non-overlapping intervals. Individuals who have the event in a ²⁵³

future interval are treated as right censored, with individuals who have had an event in a previous 254 interval excluded from the analysis. For example, this idea has been suggested by Joshi et al. [15], 255 where time intervals of 40-75 and 75+ were used. Although it is correct to conduct the analysis in 256 such a way, it requires defining intervals that could be seen as an arbitrary choice, with ill-defined 257 intervals leading to an incomplete understanding of the effect size distribution. Furthermore, this 258 type of modelling will not scale well with the added number of intervals as each interval requires an 259 additional parameter. Therefore, we propose a Cox PH model that allows specifying a functional 260 shape for age-specific effects. To estimate the marginal effect of SNP i in chromosome k, the general 261 form for Cox proportional hazards model for each SNP $j \in 1, ..., M$ is 262

$$\lambda_i(t) = \lambda_0(t) \exp\left(\mathbf{x}_{ij} \boldsymbol{\beta}_j(t) + \mathbf{g}_i^k \boldsymbol{\xi}_j + \mathbf{z}_i \boldsymbol{\delta}_j\right),\tag{2}$$

$$\boldsymbol{\beta}_j(t) = \boldsymbol{\beta}_j^0 + \boldsymbol{\beta}_j^1(t - t_0), \tag{3}$$

where β_j^0 is the intercept term, effectively estimating the effect size at time t_0 and β_j^1 is the slope 270 showing how much the effect changes each year. It is possible to define any other parametric 271 shape, for example, the exponential decay function could be a natural choice. However, in the 272 first experiments on real data, the linear effect size change gave a higher likelihood compared 273 to exponential decay models. Hence, we decided to resort to the linear effect size model that is 274 easier to interpret and the variance function can be represented without Taylor expansion-based 275 approximations. Given the effect size function definition, we can calculate the variance at each time 276 point t as 277

$$Var(\boldsymbol{\beta}_{j}(t)) = Var(\boldsymbol{\beta}_{j}^{0}) + (t - t_{0})^{2} Var(\boldsymbol{\beta}_{j}^{1}) + 2(t - t_{0}) Cov(\boldsymbol{\beta}_{j}^{0}, \boldsymbol{\beta}_{j}^{1}),$$
(4)

where $Var(\boldsymbol{\beta}_{j}^{0})$, $Var(\boldsymbol{\beta}_{j}^{1})$ and $Cov(\boldsymbol{\beta}_{j}^{0}, \boldsymbol{\beta}_{j}^{1})$ can be estimated from the Hessian of the Cox model. ²⁷⁸ We use the linear effect change definition from equation 3 to test whether there exists a change in ²⁷⁹ the effect size across the lifespan. As including the genetic values from other chromosomes shares ²⁸⁰ properties with mixed modelling, we are going to refer to this model as the CAMP model (Cox ²⁸¹ Age-specific Mixed Proportional hazard). ²⁸²

At each time point t we can define the test statistic function $\chi_j^2(t)$ for SNP j as the square of the ratio of effect size and the standard error of the effect size 284

$$\chi_{j}^{2}(t) = \left(\frac{\hat{\beta}_{j}^{0} + \hat{\beta}_{j}^{1}(t - t_{0})}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{0}) + (t - t_{0})^{2}\widehat{Var}(\hat{\beta}_{j}^{1}) + 2(t - t_{0})\widehat{Cov}(\hat{\beta}_{j}^{0}, \hat{\beta}_{j}^{1})}}\right)^{2}.$$
(5)

All that remains is to estimate \mathbf{g}_i^k , the genetic predictor from all other chromosomes other than 285

the SNP j. To do this, we use a BayesW model [1] which assumes that for an individual i the age-at-onset of a disease y_i has Weibull distribution, with a re-parameterisation of the model to represent the mean and the variance of the logarithm of the phenotype as 288 289 289 289 289

$$E(\log(y_i)|\mu, \boldsymbol{\beta}, \boldsymbol{\delta}, \alpha) = \mu + \sum_{\varphi=1}^{\Phi} \boldsymbol{X}_{\varphi i} \boldsymbol{\beta}_{\varphi} + \boldsymbol{Z}_i \boldsymbol{\delta},$$
(6)

$$Var(\log(y_i)|\mu,\beta,\delta,\alpha) = \frac{\pi^2}{6\alpha^2}$$
(7)

where X_{φ} is a standardised genotype matrix containing SNPs allocated to group φ , μ is an intercept, 290 β_{φ} is the vector of SNP effects in group φ , Z_i are additional covariates (such as sex or genetic 291 principal components), δ are the additional covariate effect estimates and α is the Weibull shape 292 parameter. For each group, we assume that β_{φ} are distributed according to a mixture of Gaussian 293 components with mixture-specific proportions π_{φ} and mixture variances $\sigma_{\varphi 1}^2, \ldots, \sigma_{\varphi L}^2$ and a Dirac 294 delta at zero which induces sparsity: 295

$$\boldsymbol{\beta}_{\varphi j} \sim \boldsymbol{\pi}_{\varphi 0} \delta_0 + \boldsymbol{\pi}_{\varphi 1} \mathcal{N}(0, \sigma_{1\varphi}^2) + \dots + \boldsymbol{\pi}_{\varphi L} \mathcal{N}(0, \sigma_{\varphi L}^2), \tag{8}$$

where L is the number of mixture components. We estimated the hyperparameters such as genetic 296 variance and prior inclusion probability by grouping markers into MAF-LD bins as recent theory 297 suggests this yields improved estimation [16] and here, 20 MAF-LD groups that were defined as 298 MAF quintiles and then quartiles within each of those MAF, quintiles split by the LD score. The 299 cut-off points for creating the MAF quintiles were 0.006, 0.013, 0.039, 0.172; the cut-off points 300 for creating LD score quartiles were 2.11, 3.08, 4.51 for the first; 3.20, 4.71, 6.84 for the second; 301 4.70, 6.89, 9.94 for the third; 7.65, 11.01, 15.70 for the fourth and 10.75, 15.10, 21.14 for the fifth 302 MAF quintile, exactly as in the age-at-menopause analysis by Ojavee et al. [1]. The posterior mean 303 BayesW model estimates of β_{φ} are then used to create \mathbf{g}_{i}^{k} , the genetic predictor from all other 304 chromosomes other than the SNP j. This gives a two-step LOCO (leave-one-chromosome-out) 305 approach, where first a BayesW model is used to estimate the genetic predictor and then a marginal 306 age-specific Cox proportional hazards model is used for the second step. Next, we discuss how we 307 can conduct significance testing in the second step in an efficient manner, whilst ensuring that type 308 I error is bounded below the fixed threshold α even with a more complex model. 309

Significance testing

310

289

We demonstrate that to limit type I error rate below α and given the null hypothesis of no effect at SNP j ($\beta_j^0 = 0$, $\beta_j^1 = 0$), it is sufficient to compare the test statistic $\chi_j^2(t^*)$ with the $\chi_{df=2}^2 1 - \alpha$ quantiles at any time point t^* .

We will naturally assume that $\widehat{Var}(\hat{\beta}_j^0) > 0$ and $\widehat{Var}(\hat{\beta}_j^1) > 0$. As $\chi_j^2(t)$ is twice differentiable, it ³¹⁴ is possible to find its respective first and second derivative. This will give us two extreme points t^* ³¹⁵ at which the $\frac{d}{dt}\chi_j^2(t^*) = 0$. Then, the χ^2 -score has a local maximum if $\frac{d^2}{dt^2}\chi_j^2(t^*) < 0$ or the χ^2 -score ³¹⁶ has a local minimum weakest if $\frac{d^2}{dt^2}\chi_j^2(t^*) > 0$. It can be shown that the function $\chi_j^2(t)$ has two ³¹⁷ extreme points located at ³¹⁸

$$t_1^* = -\frac{\hat{\beta}_j^0}{\hat{\beta}_j^1} + t_0.$$
(9)

$$t_2^* = \frac{\hat{\boldsymbol{\beta}}_j^0 \widehat{Cov}(\hat{\boldsymbol{\beta}}_j^0, \hat{\boldsymbol{\beta}}_j^1) - \hat{\boldsymbol{\beta}}_j^1 \widehat{Var}(\hat{\boldsymbol{\beta}}_j^0)}{\hat{\boldsymbol{\beta}}_j^1 \widehat{Cov}(\hat{\boldsymbol{\beta}}_j^0, \hat{\boldsymbol{\beta}}_j^1) - \hat{\boldsymbol{\beta}}_j^0 \widehat{Var}(\hat{\boldsymbol{\beta}}_j^1)} + t_0.$$
(10)

Using the second derivative, it can be shown that $\chi_j^2(t)$ will always have a (global) maximum at 319 t_2^* and a (global) minimum $(\chi^2(t_1^*) = 0)$ at t_1^* . We find that in the limiting cases test statistic is testing the significance of the slope $\lim_{t\to\infty} \chi_j^2(t) = \frac{(\beta_j^1)^2}{Var(\beta_j^1)}$ and $\lim_{t\to-\infty} \chi_j^2(t) = \frac{(\beta_j^1)^2}{Var(\beta_j^1)}$. As the 320 321 domain of $\chi_j^2(t)$ is the set of positive real numbers and there are no breakpoints in the function, 322 then $\chi_j^2(t)$ is bounded within interval $[\chi_j^2(t_1^*), \chi_j^2(t_2^*)]$. 323

We are especially interested in the distribution of the maximum possible χ^2 -statistic $\chi_i^2(t_2^*)$ under 324 the null hypothesis that both $\beta_i^0 = 0$ and $\beta_i^1 = 0$. 325

Lemma 1. Under the null hypothesis that both $\beta_j^0 = 0$ and $\beta_j^1 = 0$, the chi-squared statistic 326 evaluated at the maximum point $t_2^* \chi_j^2(t_2^*)$ follows a $\chi_{df=2}^2$ distribution: 327

$$\chi_j^2(t_2^*) \sim \chi_{df=2}^2.$$
(11)

Proof. We define $r := \frac{\widehat{Cov}(\hat{\beta}_j^0, \hat{\beta}_j^1)}{\sqrt{\widehat{Var}(\hat{\beta}_j^0)\widehat{Var}(\hat{\beta}_j^1)}}$ and we express $\chi_j^2(t_2^*)$ such that it would be a sum of two 328 uncorrelated random variable 329

$$\chi_{j}^{2}(t_{2}^{*}) = \frac{(\hat{\beta}_{j}^{0})^{2}\widehat{Var}(\hat{\beta}_{j}^{1}) - 2\hat{\beta}_{j}^{0}\hat{\beta}_{j}^{1}\widehat{Cov}(\hat{\beta}_{j}^{0}, \hat{\beta}_{j}^{1}) + (\hat{\beta}_{j}^{1})^{2}\widehat{Var}(\hat{\beta}_{j}^{0})}{\widehat{Var}(\hat{\beta}_{j}^{0})\widehat{Var}(\hat{\beta}_{j}^{1}) - \widehat{Cov}(\hat{\beta}_{j}^{0}, \hat{\beta}_{j}^{1})^{2}} = \frac{\frac{(\hat{\beta}_{j}^{0})^{2}}{\widehat{Var}(\hat{\beta}_{j}^{0})} - \frac{2r\hat{\beta}_{j}^{0}\hat{\beta}_{j}^{1}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{0})}} + \frac{(\hat{\beta}_{j}^{1})^{2}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{1})}}}{1 - r^{2}} = \frac{\frac{(\hat{\beta}_{j}^{0})^{2}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{0})}} - \frac{2r\hat{\beta}_{j}^{0}\hat{\beta}_{j}^{1}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{0})}} + \frac{(\hat{\beta}_{j}^{1})^{2}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{1})}}}{1 - r^{2}} = \frac{(\hat{\beta}_{j}^{0})^{2}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{0})}} - \frac{2r\hat{\beta}_{j}^{0}\hat{\beta}_{j}^{1}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{1})}} + \frac{(\hat{\beta}_{j}^{1})^{2}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{1})}}}{1 - r^{2}} = \frac{(\hat{\beta}_{j}^{0})^{2}}{1 - r^{2}} + \frac{(\hat{\beta}_{j}^{0})^{2}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{1})}} + \frac{(\hat{\beta}_{j}^{1})^{2}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{1})}}}{1 - r^{2}} + \frac{(\hat{\beta}_{j}^{0})^{2}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{1})}} + \frac{(\hat{\beta}_{j}^{0})^{2}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{1})}} + \frac{(\hat{\beta}_{j}^{0})^{2}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{1})}}}{1 - r^{2}} + \frac{(\hat{\beta}_{j}^{0})^{2}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{1})}} + \frac{(\hat{$$

Under the null hypothesis of $\beta_j^0 = 0$ and $\beta_j^1 = 0$ we know that $\frac{\hat{\beta}_j^0}{\sqrt{\widehat{Var}(\hat{\beta}_j^0)}} \sim N(0,1)$ and $\frac{\hat{\beta}_j^1}{\sqrt{\widehat{Var}(\hat{\beta}_j^1)}} \sim 330$ N(0,1) and therefore 331

$$\begin{pmatrix} \frac{\hat{\beta}_{j}^{0}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{0})}} - r \frac{\hat{\beta}_{j}^{1}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{1})}} \\ \sqrt{1 - r^{2}} \frac{\hat{\beta}_{j}^{1}}{\sqrt{\widehat{Var}(\hat{\beta}_{j}^{1})}} \end{pmatrix} \sim N\left(\begin{pmatrix} 0\\0 \end{pmatrix}, \begin{pmatrix} 1 - r^{2} & 0\\0 & 1 - r^{2} \end{pmatrix}\right).$$
(13)

The last result implies that under the null of $\beta_j^0 = 0$ and $\beta_j^1 = 0$ the equation 12 is a sum of two 332 uncorrelated standard Gaussian random variables squared which means that $\chi_i^2(t_2^*)$ is from the 333 chi-squared distribution with degrees of freedom of 2. 334

This naturally gives us a rule for hypothesis testing at time t_2^* . If the test fails to disprove the 336 null hypothesis at time t_2^* , it will fail to disprove the null hypothesis at any possible t. If the test 337 accepts the alternative hypothesis, it means that there must exist an interval (or at least one point) 338 at which the variable has an effect on the phenotype. 339

Furthermore, we can show that the quantiles of $\chi^2_{df=2}$ distribution result in a stringent enough test at any time point.

Lemma 2. Suppose that we have estimated effect sizes β_j^0 and β_j^1 from a linear effect change model $\beta_j(t) = \beta_j^0 + \beta_j^1(t-t_0)$ and that the null hypothesis of $\beta_j^0 = 0$ and $\beta_j^1 = 0$ holds. Then, for every time point t, the probability of type I error (α) is bounded when using the χ_2^2 distribution $1 - \alpha$ quantile as a critical value.

Proof. To prove the lemma, we need to demonstrate that $1 - \alpha$ quantile of χ_2^2 distribution $(q_{1-\alpha})_{346}$ is greater than $1 - \alpha$ quantile of $\chi^2(t)$ at any time point t under the null hypothesis $\boldsymbol{\beta}_j^0 = 0$ and $_{347}^{346}$ $\boldsymbol{\beta}_j^1 = 0$. Suppose that the maximum test statistic value is achieved at t_2^* with value $\chi_j^2(t_2^*)$.

We suppose in contradiction that under the null hypothesis there exists some time point $t_* \neq t_2^*$ at which the distribution of $\chi_j^2(t_*)$ would have a higher $1 - \alpha$ quantile value $\tilde{q}_{1-\alpha}$ than the $1 - \alpha$ quantile of $\chi_{df=2}^2$ distribution $q_{1-\alpha}$:

$$\tilde{q}_{1-\alpha} > q_{1-\alpha}.$$

Given this, we can write the following inequalities

$$\alpha = P(\chi_j^2(t_*) > \tilde{q}_{1-\alpha}) < P(\chi_j^2(t_*) > q_{1-\alpha}) < P(\chi_j^2(t_2^*) > q_{1-\alpha}) = \alpha,$$

where the first inequality follows from the contradiction and the second inequality from the fact that $\chi_j^2(t_*)$ is the maximum possible value of the test statistic. The inequalities result in a contradiction which therefore proves the lemma. 351

352

An important corollary of this result is that we can use $\chi^2_{df=2}$ quantiles to do statistical testing at any time point and doing tests at (many) different time points will not increase type I error. For example, we can simultaneously test the significance of the slope (corresponds to $\lim_{t\to\infty} \chi^2_j(t)$) and significance at t_2^* (using $\chi^2_j(t_2^*)$) at the $1 - \alpha$ -quantile of $\chi^2_{df=2}$ distribution while limiting the type I error at α as given the effect and variance estimates.

UK Biobank data

358

We first restricted our analysis to a sample of European-ancestry UK Biobank individuals. To 359 infer ancestry, we used both self-reported ethnic background (UK Biobank field 21000-0), selecting 360 coding 1, and genetic ethnicity (UK Biobank field 22006-0), selecting coding 1. We projected the 361 488,377 genotyped participants onto the first two genotypic principal components (PC) calculated 362 from 2,504 individuals of the 1,000 Genomes project. Using the obtained PC loadings, we then 363 assigned each participant to the closest 1,000 Genomes project population, selecting individuals 364 with PC1 projection < absolute value 4 and PC2 projection < absolute value 3. Samples were also 365 excluded based on UK Biobank quality control procedures with individuals removed of (i) extreme 366

heterozygosity and missing genotype outliers; (ii) a genetically inferred gender that did not match 367 the self-reported gender; (iii) putative sex chromosome aneuploidy; (iv) exclusion from kinship 368 inference; (v) withdrawn consent. We used genotype probabilities from version 3 of the imputed 369 autosomal genotype data provided by the UK Biobank to hard-call the genotypes for variants with 370 an imputation quality score above 0.3. The hard-call-threshold was 0.1, setting the genotypes 371 with probability ≤ 0.9 as missing. From the good quality markers (with missingness less than 372 5% and p-value for Hardy-Weinberg test larger than 10^{-6} , as determined in the set of unrelated 373 Europeans), we selected those with minor allele frequency (MAF) > 0.0002 and rs identifier, in the 374 set of European-ancestry participants. We then took the overlap with the Estonian Biobank data 375 described below to give a final set of 8.7 million SNPs using both autosomal chromosomes and the 376 X chromosome. This provides a set of high-quality SNP markers present across both discovery and 377 prediction data sets. 378

We created the phenotypic data of age-at-menopause similarly to [1]. We used UKB field 3581 to 379 obtain the time if available, and we excluded from the analysis 1) women who had reported having 380 and later not having had menopause or vice versa, 2) women who said they had menopause but there 381 is no record of the time of menopause (UKB field 2724), 3) women who have had a hysterectomy 382 or the information about this is missing (UKB field 3591), 4) women whose menopause is before 383 age 33 or after 65. Within the UK Biobank data, there were a total of 173,424 unrelated (only one 384 person kept from second-degree or closer relative pairs) European ancestry women, out of which 385 125,697 had experienced menopause and 47,727 had not had menopause based on data field 2724. 386 For computational convenience when conducting the joint BayesW analysis we created an additional 387 subset of markers by removing markers in very high LD, through the selection of the highest MAF 388 marker from any set of markers with LD $R^2 \ge 0.8$ within a 1Mb window. These filters resulted in a 389 data set with 173,424 individuals and 2,174,071 markers for the first-step estimation of the LOCO 390 genetic predictors and then in the second-step age-specific Cox Proportional hazards we analysed 391 8.7 million SNPs using both autosomal chromosomes and the X chromosome. 392

Estonian Biobank data

To replicate the findings we used the Estonian Biobank with 70,082 women (22,740 with menopause, 394 47,342 without menopause). In the Estonian Biobank data, there were 195,432 individuals genotyped 395 on Illumina Global Screening (GSA) arrays, which were imputed to an Estonian reference created 396 from the whole genome sequence data of 2,244 participants [17]. From 11,130,313 markers with 397 imputation quality score > 0.3, we selected SNPs that overlapped with those selected in the UK 398 Biobank as described above using the same SNP sets for the first and second steps of the analyses. 399

393

400

Analysis of age-at-menopause

We investigated the three questions as proposed in Figure 1: 1) we checked the interval at which 401 there is a significant effect, 2) we tested the significance at ages at which the variants had the most 402 evidence for an effect, 3) we tested for the existence of an age-specific effect. 403

Interval at which variant is significant

420

We evaluated the test statistic function using Equation 5 at ages 41, 43, 45, 47, 49, 51, 53, 55 and 405 calculated the p-values using the $\chi^2_{df=2}$ distribution quantiles as suggested by our theory above. On 406 these results, at each age, we applied the clumping procedure (using plink 1.9 [18]) with a window 407 size of 1Mb, LD threshold of $r^2 = 0.05$, p-value threshold for index SNPs of $p = 5 \cdot 10^{-8}$ and no 408 p-value threshold for other SNPs belonging to a clump of an index SNP. To detect clumps with 409 an independent signal, we applied the COJO procedure [19] implemented in GCTA software [20] 410 with a window size of 1Mb and the SNPs were considered independent if the p-value in the joint 411 model was less than $5 \cdot 10^{-8}$. The independent index SNPs from the COJO analysis were then 412 replicated at each age in the Estonian Biobank data, with replication defined as a p-value lower 413 than 0.05 and the same effect size estimate sign as in the discovery analysis. To check the period 414 during which a SNP has a significant effect (Figure 2a), we checked whether the same SNP or a 415 SNP in the same clump also has an effect in the consecutive grid point. Specifically, we took all the 416 significant independent and replicated SNPs at ages 41 and 43, and then we checked if the index 417 SNPs of age 41 mapped directly to an index SNP at age 43 or a clump of an index SNP. Then, we 418 compared the ages 43 and 45, and iteratively so forth until 55. 419

Testing at age with the maximum effect evidence

We tested the significance at ages at which the variants had the most evidence for an effect to 421 understand the total number of significant effects and possibly identify novel loci. Furthermore, we 422 defined a period of interest between ages 45 and 52, so the significance would only be evaluated 423 during this period. That was done to avoid over-interpretation of the linear effect at uncommon 424 high or low ages. Therefore, using Equation 10 we first calculated the age t_2^* at which the test 425 statistic achieves the highest value, and secondly, we evaluated the chi-squared function (Equation 426 5) at that age t_2^* . If there time point t_2^* was outside of the interval [45,52], then we instead evaluated 427 the function at the time point where the function $\chi_i^2(t)$ achieved its maximum within the interval 428 (either age 45 or 52). We compared the chi-squared statistics with the $\chi^2_{df=2}$ distribution to calculate 429 the p-values. We applied a similar procedure to the previous case. First, we applied the clumping 430 procedure (using plink 1.9 [18]) with a window size of 1Mb, LD threshold of $r^2 = 0.05$, p-value 431 threshold for index SNPs of $p < 5 \cdot 10^{-8}$ and no p-value threshold for other SNPs belonging to a 432 clump of an index SNP. Secondly, to detect clumps with an independent signal, we applied the 433 COJO procedure [19] implemented in GCTA software [20] with a window size of 1Mb and the 434 SNPs were considered independent if the p-value in the joint model was less than $5 \cdot 10^{-8}$. We then 435 checked the independent and significant SNPs from the COJO analysis for previous association 436 signals. We removed all the markers that had a correlation of $r^2 > 0.1$ with a marker that had 437 been previously found associated with age-at-menopause using the GWAS Catalog (published until 438 April 2022) and LDtrait tool with the British in England and Scotland population. Furthermore, 439 we specifically compared our candidate set for the significant SNPs reported by Ruth et al. [9], 440 removing the markers or the markers with a correlation $r^2 > 0.1$ reported by them. Finally, we 441 checked our candidate set with the Phenoscanner database [21, 22] to find any previous associations 442 with variants of interest or variants in LD. The index SNPs not removed by the three filters were 443

then replicated at age with maximum evidence in the period [40,55] in the Estonian Biobank data, with replication defined as a p-value lower than 0.05 and the same effect estimate sign as in the discovery analysis.

Testing for an age-specific effect

To verify whether there is a genome-wide significant age-specific effect for every SNP j, we checked if the slope parameter is significantly different from 0

$$H_0: \boldsymbol{\beta}_j^1 = 0,$$

where β_i^1 is estimated from the model specified in Equation 2. The chi-squared statistic was 448 calculated as the squared ratio of the slope size estimate and standard error estimate. As this 449 quantity naturally corresponds to $\lim_{t\to\infty} \chi_i^2(t)$ where $\chi_i^2(t)$ is defined as in Equation 5, we compare 450 the test statistic again with the $\chi^2_{df=2}$ distribution quantiles to get the p-values. Similarly to two 451 previous cases, we first applied the clumping procedure (using plink 1.9 [18]) with a window size of 452 1Mb, LD threshold of $r^2 = 0.05$, p-value threshold for index SNPs of $p < 5 \cdot 10^{-8}$ and no p-value 453 threshold for other SNPs belonging to a clump of an index SNP. Secondly, to detect clumps with an 454 independent signal, we applied the COJO procedure [19] implemented in GCTA software [20] with a 455 window size of 1Mb and the SNPs were considered independent if the p-value in the joint model was 456 less than $5 \cdot 10^{-8}$. The independent index SNPs from the COJO analysis were then replicated in 457 the Estonian Biobank data, with replication defined as a p-value lower than 0.05 and the sign of the 458 slope the same as in the discovery analysis. We classified the SNPs with different levels of evidence 459 of age-specific effects. SNPs with a p-value below the nominal significance threshold (p < 0.05)460 are said to have at least weak evidence for an age-specific effect; variants with a p-value below the 461 genome-wide significance threshold $(p < 5 \cdot 10^{-8})$ are said to have at least moderate evidence for an 462 age-specific effect; variants with moderate evidence that also replicate in the Estonian Biobank are 463 considered to have strong evidence for an age-specific effect. The variants that do not fall under 464 these three categories are said to have no evidence for age-specific effects. 465

Enrichment analysis

466

We used recently presented Downstreamer software to identify genes connected to our association 467 study results through gene expression and to identify enriched pathways. We calculated test statistics 468 using Equation 5 at ages 41, 43, 45, 47, 49, 51, 53, 55 and calculated the p-values using the $\chi^2_{df=2}$ 469 distribution quantiles as suggested by our theory above. 470

Downstreamer implements a strategy that accounts for LD structure and chromosomal organiza-471 tion, operating in two steps. In the first step, gene-level prioritization scores were calculated for 472 each age group's summary statistics and a null distribution. This aggregates p-values per variant 473 into a p-value per gene while accounting for local LD structure. We aggregated all variants within a 474 25-kb window around the start and end of a gene using the non-Finnish European samples of the 475 1000 Genomes (1000G) project, Phase 3 to calculate LD. We calculated these GWAS gene pvalues 476 for all 20,327 protein-coding genes (Ensembl release v75). The gene p-values were then converted to 477 z-scores for use in subsequent analysis. These are referred to as GWAS gene z-scores. To account 478

for the long-range effects of haplotype structure, which results in genes getting similar gene z-scores, 479 we use a generalized least-squares (GLS) regression model for all regressions done in Downstreamer. 480 The GLS model takes a correlation matrix that models this gene–gene correlation. To calculate 481 this correlation matrix we first simulated 10,000 random phenotypes by drawing phenotypes from a 482 normal distribution and then associating them to the genotypes of the 1000G Phase 3 non-Finnish 483 European samples. We used only overlapping variants between the real traits and the permuted 484 GWASs to avoid biases introduced by genotyping platforms or imputation. We then calculated 485 the GWAS gene z-scores for each of the 10,000 simulated GWAS signals as described above. Next, 486 we calculated the Pearson correlations between the GWAS gene z-scores. As simulated GWAS 487 signals are random and independent of each other, any remaining correlation between GWAS gene 488 z-scores reflects the underlying LD patterns and chromosomal organization of genes. An additional 489 10,000 GWASs were simulated to empirically determine enrichment p-values and, finally, we used 490 an additional 100 simulations to estimate the FDR of Downstreamer associations. 491

In the second step, the gene-level prioritization scores were associated with the co-regulation 492 matrix and pathway annotations. We used a previously generated co-regulation matrix that is 493 based on a large multi-tissue gene network. In short, publicly available RNA-seq samples were 494 downloaded from the European Nucleotide Archive (https://www.ebi.ac.uk/ena). After QC, 495 56,435 genes and 31,499 samples covering a wide range of human cell types and tissues remained. 406 We performed a PCA on this dataset and selected 165 components representing 50% of the variation 497 that offered the best prediction of gene function. We then selected the protein-coding genes and 498 centred and scaled the eigenvectors for these 165 components (mean = 0, s.d. = 1) such that each 499 component was given equal weight. The first components mostly describe tissue differences, so this 500 normalization ensures that tissue-specific patterns do not disproportionately drive the co-regulation 501 matrix. The co-regulation matrix is defined as the Pearson correlation between the genes from 502 the scaled eigenvector matrix. The diagonal of the co-regulation matrix was set to zero to avoid 503 the correlation with itself having a disproportionate effect on the association to the GWAS gene 504 z-scores. Finally, we converted the Pearson r to z-scores. 505

To identify pathway and disease enrichments, we used the following databases: Human Phenotype 506 Ontology (HPO), Kyoto Encyclopaedia of Genes and Genomes (KEGG), Reactome and Gene 507 Ontology (GO) Biological Process, Cellular Component and Molecular Function. We have previously 508 predicted how much each gene contributes to these gene sets, resulting in a z-score per pathway 509 or term per gene. We collapsed genes into meta-genes in parallel with the GWAS step, to ensure 510 compatibility with the GWAS gene z-score following the same procedure as in the GWAS pre-511 processing. Meta-gene z-scores were calculated as the z-score sum divided by the square root of the 512 number of genes. Finally, all pathway z-scores were scaled (mean = 0, s.d. = 1). 513

For each GWAS, both real and simulated, we carried out the rank-based inverse normal transformation of GWAS z-scores to ensure that outliers would not have disproportionate weights. Owing to limitations in the PASCAL methodology that result in ties at a minimum significance level of $1x10^{12}$ for highly significant genes, we used the minimum SNP p-value from the GWAS to identify the most significant gene and resolve the tie. We then used a linear model to correct for gene length, as longer genes will typically harbour more SNPs. Sometimes, two (or more) genes will be so close to one another that their GWAS gene z-scores are highly correlated, violating the assumptions of 520

the linear model. Thus, genes with a Pearson correlation $r \ge 0.8$ in the 10,000 GWAS permutations 521 were collapsed into 'meta-genes' and treated as one gene. Meta-gene z-scores were averaged across 522 the input z-scores. Lastly, the GWAS z-scores of the meta-genes were scaled (mean = 0, s.d. =523 1). We used a GLS regression to associate the GWAS gene z-scores to the pathway z-scores and 524 co-regulation z-scores (described below). These two analyses result in pathway enrichments and 525 core gene prioritizations, respectively. We used the gene–gene correlation matrix derived from the 526 10,000 permutations as a measure of conditional covariance of the error term (ω) in the GLS to 527 account for the relationships between genes due to LD and proximity. The pseudo-inverse of ω is 528 used as a substitute for ω^{-1} . 529

The formula of the GLS is $\beta = (X^T \omega^{-1} X)^{-1} X^T \omega^{-1} y$, where β is the estimated effect size of a 530 pathway, term or gene from the co-regulation matrix, ω is the gene–gene correlation matrix, X is 531 the design matrix of real GWAS z-scores and y is the vector of gene z-scores per pathway, term 532 or gene from the co-regulation matrix. As we standardized the predictors, we did not include an 533 intercept in the design matrix and X contains only one column with the real GWAS gene z-scores. 534 We estimated β for the 10,000 random GWASs in the same way and subsequently used them to 535 estimate the empirical p-value for β . We present full results for each age in Tables S3 to S10. 536

Genetic correlations

We used LD Score regression to calculate genetic correlations among the test statistics generated using Equation 5 at ages 41, 43, 45, 47, 49, 51, 53, 55, and among these ages and other phenotypes 539 using publicly available GWAS summary data. We present these estimates in Figure 4. 540

Mendelian Randomisation

We calculated the causal effect estimates that ANM at different ages has on various traits using 542 Mendelian Randomization (MR); a statistical method which utilizes the randomized inheritance 543 of genetic variations in the population to estimate the potential causal effect a modifiable risk 544 factor or exposure has on a health-related outcome of interest [23,24]. The genetic variants used 545 as instrumental variables (IVs) for our exposure were selected to have a genome-wide significant 546 association with the exposure $(p < 5 \cdot 10^{-8})$ and were then pruned using linkage disequilibrium (LD) 547 distance to ensure that they were independent. This was done using the 'ld clump' function of the 548 'ieugwasr' R package [25] with default settings (clump kb = 10000, clump r2 = 0.001, clump p 549 = 0.99, pop = "EUR"). After the IVs of our exposure were selected, their association effects were 550 then obtained for each of our outcome traits of interest. A single-sided t-test was carried out to 551 check if the IVs had a stronger association with the outcome than with the exposure and were 552 subsequently removed if so (for violating the MR assumptions). The two sets of association effects 553 were then harmonized and used to calculate the causal effect estimates using the Inverse Variance 554 Weighted method found in the 'TwoSampleMR' R package [26]. This analysis was repeated for each 555 varying age of our exposure. It is important to note that in the case of Educational attainment as an 556 outcome, there were little exposure IVs that overlapped with the outcome genetic variants, especially 557 as the age increased, hence in the presence of a single IV, a Wald ratio was used to calculate the 558 MR causal effect estimate. Moreover, when the trait was of a case-control nature, the effective 559

538

541

sample size was calculated using the following formula: $(4^{\circ} cases^{\circ} controls)/(cases+controls)$ [27]. 560

Author contributions

SEO and MRR conceived and designed the study. SEO and ZK conceived and derived the significance testing. SEO, LD, MP and MRR conducted the analysis. KL, KF, RM provided study oversight and contributed data. SEO and MRR wrote the paper. All authors approved the final manuscript prior to submission. 565

Author competing interests

MRR receives research funding from Boehringer Ingelheim. SEO is an employee of MSD at the time of the submission, contribution to the research occurred during the affiliation at the University of Lausanne. 569

Data availability

This project uses UK Biobank data under project 35520. UK Biobank genotypic and phenotypic data 571 is available through a formal request at (http://www.ukbiobank.ac.uk). The UK Biobank has 572 ethics approval from the North West Multi-centre Research Ethics Committee (MREC). For access 573 to be granted to the Estonian Biobank genotypic and corresponding phenotypic data, a preliminary 574 application must be presented to the oversight committee, who must first approve the project, ethics 575 permission must then be obtained from the Estonian Committee on Bioethics and Human Research, 576 and finally a full project must be submitted and approved by the Estonian Biobank. This project 577 was granted ethics approval by the Estonian Committee on Bioethics and Human Research (https: 578 //genomics.ut.ee/en/biobank.ee/data-access). Age-specific summary statistic estimates are 579 released publicly on Dryad: https://doi.org/10.5061/dryad.nvx0k6dx5. 580

Code availability

The BayesW model was executed with the software Hydra, with full open source code available at https://github.com/medical-genomics-group/hydra [28]. The scripts used to execute CAMP model is available at https://github.com/svenojavee/CAMP. R version 4.2.1 is available at https://www.r-project.org/. 585

Acknowledgements

This project was funded by an SNSF Eccellenza Grant to MRR (PCEGP3-181181), and by core funding from the Institute of Science and Technology Austria. K.L. and R.M. were supported by the Estonian Research Council grant 1911. Estonian Biobank computations were performed in the High Performance Computing Centre, University of Tartu. We thank Triin Laisk for her valuable insights and comments that helped greatly. We would like to acknowledge the participants and investigators of UK Biobank and Estonian Biobank studies. This project uses UK Biobank data under project number 35520.

586

581

561

566

References

- 1. Ojavee, S. E. *et al.* Genomic architecture and prediction of censored time-to-event phenotypes with a bayesian genome-wide analysis. *Nature Communications* **12**, 2337 (2021).
- Pedersen, E. M. et al. Accounting for age of onset and family history improves power in genome-wide association studies. The American Journal of Human Genetics 109, 417–432 (2022).
- 3. Shin, J. *et al.* Age at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study. *European Heart Journal* **43**, 4148–4157 (2022).
- Nash, Z., Al-Wattar, B. H. & Davies, M. Bone and heart health in menopause. Best Practice & Research Clinical Obstetrics & Gynaecology (2022).
- 5. Collaborative Group on Hormonal Factors in Breast Cancer and others. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. *The Lancet Oncology* **13**, 1141–1151 (2012).
- Murabito, J. M., Yang, Q., Fox, C., Wilson, P. W. & Cupples, L. A. Heritability of age at natural menopause in the framingham heart study. *The Journal of Clinical Endocrinology & Metabolism* 90, 3427–3430 (2005).
- 7. Stolk, L. *et al.* Meta-analyses identify 13 loci associated with age at menopause and highlight dna repair and immune pathways. *Nature genetics* **44**, 260–268 (2012).
- Day, F. R. *et al.* Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and brca1-mediated dna repair. *Nature genetics* 47, 1294–1303 (2015).
- Ruth, K. S. *et al.* Genetic insights into biological mechanisms governing human ovarian ageing. *Nature* 596, 393–397 (2021).
- Jiang, X., Holmes, C. & McVean, G. The impact of age on genetic risk for common diseases. PLoS genetics 17, e1009723 (2021).
- Winkler, T. W. *et al.* The influence of age and sex on genetic associations with adult body size and shape: a large-scale genome-wide interaction study. *PLoS genetics* **11**, e1005378 (2015).
- Levine, M. E. et al. Menopause accelerates biological aging. Proceedings of the National Academy of Sciences 113, 9327–9332 (2016).
- Ward, L. D. *et al.* Rare coding variants in dna damage repair genes associated with timing of natural menopause. *Human Genetics and Genomics Advances* 3, 100079 (2022). URL https://www.sciencedirect.com/science/article/pii/S2666247721000609.
- Robinson, M. R. *et al.* Genotype–covariate interaction effects and the heritability of adult body mass index. *Nature genetics* 49, 1174–1181 (2017).

- Joshi, P. K. *et al.* Variants near chrna3/5 and apoe have age-and sex-related effects on human lifespan. *Nature communications* 7, 1–7 (2016).
- Patxot, M. *et al.* Probabilistic inference of the genetic architecture underlying functional enrichment of complex traits. *Nature Communications* 12, 6972 (2021).
- Tasa, T. *et al.* Genetic variation in the estonian population: pharmacogenomics study of adverse drug effects using electronic health records. *European Journal of Human Genetics* 27, 442–454 (2019).
- Purcell, S. et al. Plink: a tool set for whole-genome association and population-based linkage analyses. The American journal of human genetics 81, 559–575 (2007).
- Yang, J. et al. Conditional and joint multiple-snp analysis of gwas summary statistics identifies additional variants influencing complex traits. Nature genetics 44, 369–375 (2012).
- Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis, journal=American journal of human genetics 88, 76–82 (2011). PMC3014363[pmcid].
- Staley, J. R. et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics 32, 3207–3209 (2016).
- 22. Kamat, M. A. *et al.* PhenoScanner v2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics* **35**, 4851–4853 (2019).
- 23. Sanderson, E. et al. Mendelian randomization. Nature Reviews Methods Primers 2, 6 (2022).
- 24. Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Human molecular genetics* **23**, R89–R98 (2014).
- 25. Hemani, G. ieugwasr: R interface to the ieu gwas database api. R package version 0.1 5 (2020).
- 26. Hemani, G. *et al.* The mr-base platform supports systematic causal inference across the human phenome. *eLife* **7**, e34408 (2018). URL https://elifesciences.org/articles/34408.
- Han, B. & Eskin, E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. *The American Journal of Human Genetics* 88, 586–598 (2011).
- Robinson, M. hydra (version v1.0). Zenodo (2021). URL http://doi.org/10.5281/zenodo. 4555238.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.13.23287201; this version posted March 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Supplementary Tables

SNP	$_{\rm Chr}$	Position	Eff/Oth	MAF	Nearest gene	Yearly effect change	Slope p-value	Strongest evidence p-value
rs115441717	1	17,587,645	A/G	0.005	PADI3	-0.0036	5.37×10^{-10}	7.51×10^{-10}
rs186475193	1	66,520,884	Á/T	0.003	PDE4B	-0.0036	8.05×10^{-11}	1.30×10^{-10}
rs61813814	1	178,259,880	A/G	0.004	RASAL2	-0.0035	3.34×10^{-9}	3.18×10^{-7}
rs9662346	1	246,893,259	G/A	0.271	SCCPDH	0.0039	5.59×10^{-9}	1.20×10^{-3}
rs1406295	2	27,689,700	G/A	0.393	IFT172	-0.0038	5.21×10^{-9}	1.92×10^{-50}
rs2293269	2	48,844,968	C/G	0.352	GTF2A1L*	-0.0044	3.30×10^{-11}	1.79×10^{-20}
rs117292624	3	5,813,506	Á/T	0.006	AC027119.1*	-0.0034	6.36×10^{-9}	3.66×10^{-8}
rs1317571	3	49,910,657	T/G	0.177	ACTBP13*	-0.0042	2.99×10^{-10}	5.27×10^{-12}
rs9818740	3	135,939,586	A/G	0.274	RP11-463H24.1*	-0.0042	1.35×10^{-10}	1.01×10^{-14}
rs149660889	4	7,769,181	C/T	0.006	AFAP1*	-0.0035	1.61×10^{-9}	3.36×10^{-7}
rs7661090	4	13,571,901	T/C	0.105	BOD1L1	-0.0040	3.45×10^{-10}	1.42×10^{-18}
rs11099599	4	84,367,050	A/G	0.492	HELQ	0.0048	3.28×10^{-13}	6.18×10^{-130}
rs116822956	5	6,790,631	G/T	0.024	RP11-332J15.1*	-0.0042	9.96×10^{-12}	3.42×10^{-3}
rs11737992	5	175,953,121	T/C	0.309	RNF44*	-0.0042	1.88×10^{-10}	1.58×10^{-30}
rs76706863	6	28,291,052	G/T	0.018	ZSCAN31*	-0.0036	3.73×10^{-9}	1.27×10^{-6}
rs138131857	6	29,654,098	A/G	0.018	ZFP57*	-0.0041	2.80×10^{-11}	1.66×10^{-10}
rs11752373	6	90,583,601	A/T	0.045	CASP8AP2	-0.0037	3.79×10^{-9}	3.22×10^{-6}
rs140020429	6	109,831,159	T/C	0.006	AK9	-0.0034	4.88×10^{-9}	2.77×10^{-6}
rs117109951	7	123,057,448	C/T	0.003	IQUB*	-0.0034	6.25×10^{-9}	1.06×10^{-6}
rs10093345	8	37,872,776	C/T	0.259	EIF4EBP1*	-0.0060	2.33×10^{-18}	3.02×10^{-98}
rs76637775	8	69,027,721	G/A	0.008	PREX2	-0.0036	4.68×10^{-9}	7.68×10^{-7}
rs138790299	8	80,383,022	G/A	0.003	RP11-758H6.1*	-0.0035	6.67×10^{-10}	3.18×10^{-7}
rs112136293	8	135,941,782	A/T	0.003	RP11-1057B8.2*	-0.0035	1.11×10^{-9}	1.24×10^{-6}
rs117273292	9	91,945,999	C/T	0.03	SECISBP2	-0.0037	1.72×10^{-9}	9.40×10^{-7}
rs113357099	10	75,065,684	A/G	0.083	TTC18	0.0041	3.57×10^{-9}	8.83×10^{-4}
rs79293542	10	97,809,854	C/T	0.034	CCNJ*	-0.0042	1.02×10^{-11}	1.80×10^{-26}
rs11245450	10	126,658,075	A/G	0.420	ZRANB1	-0.0039	3.67×10^{-9}	9.68×10^{-32}
rs655139	11	102,269,679	G/T	0.082	TMEM123	-0.0038	4.45×10^{-9}	2.49×10^{-2}
rs3782232	12	57,116,249	A/G	0.071	NACA	-0.0041	1.64×10^{-10}	5.04×10^{-64}
rs80256675	12	68,088,664	C/A	0.007	RP11-43N5.1*	-0.0036	2.10×10^{-9}	2.86×10^{-6}
rs11180609	12	76,040,392	C/T	0.063	RP11-114H23.1	-0.0040	4.60×10^{-10}	7.93×10^{-12}
rs145313906	12	83,821,558	A/T	0.003	RP11-384P14.1*	-0.0038	7.07×10^{-12}	5.35×10^{-12}
rs2954111	12	122,134,415	C/T	0.36	TMEM120B*	-0.0048	1.45×10^{-13}	2.45×10^{-17}
rs7322160	13	61,061,456	C/T	0.328	TDRD3	0.0045	1.81×10^{-11}	1.89×10^{-42}
rs146576015	16	60,155,191	G/A	0.010	RP11-430C1.1*	-0.0035	6.00×10^{-9}	4.52×10^{-8}
rs140438673	16	85,217,665	A/G	0.007	CTC-786C10.1	-0.0035	6.05×10^{-9}	2.29×10^{-8}
rs13331995	16	89,912,063	C/T	0.346	SPIRE2	-0.0045	7.59×10^{-12}	2.90×10^{-29}
rs62097189	18	32,191,404	G/A	0.003	DTNA	-0.0034	2.22×10^{-9}	1.13×10^{-12}
rs148228698	19	2,417,585	A/G	0.008	TMPRSS9	-0.0035	6.61×10^{-9}	2.50×10^{-7}
rs7253685	19	55,845,386	G/A	0.378	TMEM150B	-0.0067	2.25×10^{-24}	1.57×10^{-70}
rs16991615	20	5,948,227	A/G	0.066	MCM8	0.0091	1.13×10^{-36}	1.13×10^{-36}
rs5951636	x	21,841,633	C/T	0.377	MBTPS2*	-0.0041	3.11×10^{-10}	3.69×10^{-18}
rs12559662	х	44,155,570	T/C	0.101	EFHC2	-0.0038	3.69×10^{-9}	1.06×10^{-14}

Table S1. Regions with a genome-wide significant age-specific effect on age-atmenopause not replicated in the Estonian Biobank. Although these SNPs did not have a significant slope in the replication data set, the genome-wide significant non-zero slopes indicate that the constant effect assumption might be too stringent when analysing the effect of these variants. For each SNP we tested the significance of the slope parameter using the CAMP model. The results were then LD clumped such that the index SNPs would have a p-value below $5 \cdot 10^{-8}$ and SNPs could be added to a clump if they were 1Mb from the index SNP, they were correlated with $r^2 > 0.05$ and they were nominally significant (p < 0.05). We then used the COJO method from the GCTA software (see Methods) to find clumps with independent signals by conducting stepwise selection of index SNPs in 1Mb window and we considered SNPs independent if they had a p-value below $5 \cdot 10^{-8}$ in the joint model. The candidates for significant slope were replicated in the Estonian Biobank. Replication was defined as p-value being lower than 0.05 and the direction of the effect size same in both the original analysis and the replication analysis. The effect size estimates are reported on the log hazard scale. The column Nearest gene is mapped from the SNP using ANNOVAR software, * in that column denotes intergenic regions; chromosome X nearest gene was determined by using the UCSC Genome Browser. The column Strongest evidence p-value indicates the p-value at age when there is strongest evidence for an effect.

Supplementary Figures




Figure S1. Cumulative incidence curves of menopause. Cumulative incidence curves take into account the competing risk of death. The distributions of age-at-menopause in the UK and Estonian Biobanks are relatively similar, although more menopauses happen somewhat earlier in UK Biobank than in the Estonian Biobank.






Figure S2. QQ plot of age-at-menopause GWAS using CAMP model. The x-axis uses the $\chi^2_{df=2}$ distribution quantiles as under the null hypothesis of no effect ($\beta^0 = 0$ and $\beta^1 = 0$) the test statistic follows that distribution. The genomic inflation factor is 1.044, median of $\chi^2_{df=2}$ distribution is 1.386.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.13.23287201; this version posted March 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .




Figure S3. Distribution of ages with the most evidence for an effect size. Distribution of the ages when the maximum chi-squared statistic is achieved (calculated using Equation 10) over all SNPs and significant SNPs only. Even though the distributions have similar centres (median age of 51 and 49 for all SNPs and significant SNPs, respectively), the standard deviation of all SNP age distribution is 3.7 times higher than significant SNP age distribution.




Figure S4. Effect sizes (log HR) for nominally non-significant effects by summarising the effects between the interquartile range, 95% CI, 99% CI or 99.9% CI. We observe that compared to the significant effect sizes, the non-significant effects are much smaller and do not vary much across ages. Nominally insignificant effects are defined as p > 0.05.






Figure S5. Change in hazard for the variants with a significant age-specific effects Illustration of the effect size change for the variants with an age-specific effects in Table 2.




Figure S6. Sensitivity analysis for a model with and without adjusting hormone replacement therapy (HRT) as a time-varying covariate. Log hazard ratio effect size estimates for the 312 age-at-natural menopause (ANM) associations with (x-axis) and without (y-axis) HRT as covariate. The effect sizes shown are the age between 45-52 where the maximum χ^2 statistic value was obtained for either model.